Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/02/2026 ,inter alia, to consider and approve the Audited ....
SANOFICONR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi Consumer Healthcare India has informed the stock exchanges that its Board of Directors will meet on 25th February 2026 to consider and approve the Audited Financial Statements for the quarter and financial year ended 31st December 2025. The company follows a January–December financial year, so this meeting covers Q3 results and the full-year audited results. The trading window for insiders has been closed from 1st January 2026 to 27th February 2026 in line with the company's insider trading code. No financial numbers or business updates have been shared in this intimation — those will come after the board meeting on 25th February.
This is a routine regulatory intimation with no immediate impact on the stock. Investors should watch for the actual audited results on/after 25th February 2026, as the FY-end numbers will be the key catalyst. The insider trading window closure suggests material financial information will be disclosed shortly.